Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new screening test, funded by NIHR Oxford BRC, is being hailed the most efficient way to indicate risk of colorectal cancer.

First stage UK research, published today, shows that an advanced computer algorithm technology can successfully indicate levels of risk by analysing previous blood test results in patients’ existing medical records.

The paper, ‘Evaluation of a prediction model for colorectal cancer: retrospective analysis of 2.5 million patient records’, is published today in the journal Cancer Medicine.

Advances in algorithm technology – a mathematical analysis of data – have led to the ability to search ultra-rapidly through existing NHS records to determine whether a patient is at risk of colorectal cancer.

This has the potential to save lives through early detection as well as reducing the need for unnecessary costly and invasive tests.

The algorithm, established in Tel Aviv and shown to work on the Israeli population, has now been trialled in the very different UK population.

This radically different approach has been tested over the past two years by Oxford University and funded by the NIHR Oxford Biomedical Research Centre.

Read more (Oxford Biomedical Research Centre website)

Similar stories

Same genome, different worlds: How a similar brain causes sexually dimorphic behaviours

General Research

A new paper from Department of Physiology, Anatomy & Genetics's Centre for Neural Circuits and Behaviour has shown how males and females are programmed differently in terms of sex.

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.